AxoGen, Inc. (AXGN) Given Average Recommendation of “Buy” by Analysts
AxoGen, Inc. (NASDAQ:AXGN) has received a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $15.90.
Several research analysts recently commented on the stock. BidaskClub lowered shares of AxoGen from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Leerink Swann assumed coverage on shares of AxoGen in a report on Monday, July 31st. They issued an “outperform” rating and a $22.00 price target on the stock. ValuEngine upgraded shares of AxoGen from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Cantor Fitzgerald assumed coverage on shares of AxoGen in a report on Thursday, June 29th. They issued an “overweight” rating and a $18.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and issued a $14.00 price target (down previously from $17.00) on shares of AxoGen in a report on Friday, May 19th.
ILLEGAL ACTIVITY NOTICE: “AxoGen, Inc. (AXGN) Given Average Recommendation of “Buy” by Analysts” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/19/axogen-inc-axgn-given-average-recommendation-of-buy-by-analysts.html.
AxoGen (AXGN) opened at 15.55 on Friday. The firm’s 50-day moving average is $15.90 and its 200 day moving average is $13.10. The firm’s market cap is $516.88 million. AxoGen has a 12-month low of $7.65 and a 12-month high of $17.25.
AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.02. AxoGen had a negative net margin of 27.50% and a negative return on equity of 114.64%. The firm had revenue of $15.20 million for the quarter, compared to analyst estimates of $14.40 million. During the same quarter last year, the firm posted ($0.09) earnings per share. AxoGen’s revenue for the quarter was up 46.2% compared to the same quarter last year. Equities research analysts predict that AxoGen will post ($0.31) EPS for the current year.
Several hedge funds have recently bought and sold shares of AXGN. Bank of America Corp DE raised its stake in AxoGen by 8.7% in the first quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock worth $106,000 after buying an additional 814 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in AxoGen by 0.9% in the first quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock worth $113,000 after buying an additional 93 shares in the last quarter. Thompson Davis & CO. Inc. raised its stake in AxoGen by 575.0% in the second quarter. Thompson Davis & CO. Inc. now owns 6,750 shares of the medical equipment provider’s stock worth $113,000 after buying an additional 5,750 shares in the last quarter. Campbell & CO Investment Adviser LLC raised its stake in AxoGen by 3.2% in the first quarter. Campbell & CO Investment Adviser LLC now owns 11,055 shares of the medical equipment provider’s stock worth $116,000 after buying an additional 341 shares in the last quarter. Finally, TFS Capital LLC purchased a new stake in AxoGen during the first quarter worth about $120,000. Institutional investors own 64.63% of the company’s stock.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.